摘要
目的探讨血清β2微球蛋白(β2-MG)和乳酸脱氢酶(LDH)在判断非霍奇金淋巴瘤(NHL)有无骨髓浸润及治疗效果中的意义。方法回顾性分析106例经病理确诊的NHL初治患者,按骨髓涂片检查结果分为淋巴瘤细胞白血病组27例(淋瘤白组),有骨髓浸润组26例(浸润组),无骨髓浸润组53例(无浸润组)。分别于化疗前后检测血清β2-MG和LDH水平,比较3组间有无差异。结果 3组患者β2-MG水平比较差异有统计学意义(P<0.01),其中浸润组和淋瘤白组β2-MG水平均高于无浸润组(P<0.01);淋瘤白组β2-MG水平高于浸润组(P<0.01)。3组患者LDH水平比较差异有统计学意义(P<0.01),其中浸润组和淋瘤白组LDH水平均高于非浸润组(P<0.01)。3组患者应用化疗药物治疗后β2-MG和LDH水平均有所下降,差异有统计学意义(P<0.05)。结论β2-MG和LDH可作为NHL患者是否存在骨髓浸润及其治疗效果的临床判断指标。
Objective To discuss the importance of scram β2 - MG ( beta 2 microglobulin) and LDH ( lactate dehy- drogenase) in deciding whether there is bone marrow infiltration or not in non - Hedgkin's lymphoma (NHL) and to discuss their significance in treatment. Methods 106 patients were chosen as research objects. They are all first - visit patients. By bone marrow aspiration, 27 patients were diagnosed as lymphoma cell leukemia ( lymphoma cell leukemia group), 26 patients as NHL with bone marrow infiltration (infiltration group) and 53 patients without bone marrow infiltration (no infiltration group) . The level of serum β2 - MG and LDH were detected and compared before and after treatment. Results There was statistical difference among the 3 groups in β2 -MG levels (P 〈0. 01 ) . Infiltration group and lymphoma cell leukemia group. The levels of β2 -MG in infiltration group and lymphoma cell leukemia group were higher than that in no infiltration group ( P 〈 0. 01 ) . The level of β2 - MG in lymphoma cell leukemia group was higher than that in infiltration group (P 〈0. 01 ) . There was statistical difference a- mong the 3 groups in LDH levels. The levels of LDH in infiltration group and lymphoma cell leukemia group were higher than that in no infdtration group (P 〈0. 01 ) . The level of LDH in lympbema cell leukemia group was higher than that in infiltration group ( P 〈 0. 01 ) . The levels of β2 - MG and LDH among the 3 groups decreased after chemotherapy drags treatment ( P 〈 0. 05 ). Condusion β2 - MG and LDH can be used as indicators in judging whether there is bone marrow infdtration or not and they are important clinical therapeutic markers of NHL.
出处
《中国全科医学》
CAS
CSCD
北大核心
2011年第36期4160-4163,共4页
Chinese General Practice
基金
沈阳市科学技术项目(F10-218-1-00)
关键词
淋巴瘤
非霍奇金
Β2微球蛋白
L-乳酸脱氢酶
Lymphoma, non - Hodgkin
Beta 2 - microglobulin
L - lactate dehydrogenase